Serum IL-27, IL-23 and IL-35 Levels in Neuromyelitis Optica Spectrum Disorders with Aquaporin-4 and Multiple Sclerosis (P6.415)

Objective: To assess the role of IL-12 family members including IL-27, IL-23 and IL-35 in the pathogenesis of NMOSD and MS. Background: The interleukin 12 (IL-12) family, namely IL-27, IL-23 and IL-35, has been reported to play important roles in autoimmune diseases such as neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS). Design/Methods: We determined their serum levels in patients with MS (n=29), NMOSD (n=30), and healthy control subjects (n=21) by ELISA and assessed potential correlations with clinical characteristics. Results: There was no difference in regard to the serum levels of IL-23 and IL-27 among groups. It was shown that serum IL-35 levels in patients with NMOSD were higher than those with MS and healthy controls (both, p Conclusions: Our findings revealed that the increased IL-35 levels, but not IL-23 and IL-27, in NMOSD patients might be a biomarker and might represent potential therapeutic cytokine for treating the disease. Study Supported by: NA Disclosure: Dr. Idiman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Teva, Genzyme, Bayer, Roche. Dr. Kaya has nothing to disclose. Dr. Hasankoyoglu has nothing to disclose. Dr. Keskin has nothing to disclose. Dr. Tasdemir has nothing to disclose. Dr. Altun has nothing to disclose.